DLCL
DR LALCHANDANI LABS financials
- Market cap
- ₹8 Cr
Quarterly results
Q4 FY26: revenue up 2.4%, net profit down 118.3% against the same quarter last year.
| Line item | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 3 | 2 | 2 −7% | 2 −16% | 2 −25% | 2 +2% |
| EBITDA | -0 | 0 | 0 | 1 | 1 +400% | 1 +96% | 0 −26% | 0 −87% |
| Net profit | -1 | -1 | -0 | 1 | 0 +115% | 0 +146% | 0 +322% | -0 −118% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −59.2% 1Y
1Y: ₹19.21 on 3 Sept 2025 → ₹7.84. High ₹19.21 (3 Sept 2025), low ₹6.28 (12 Aug 2026).
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹9 Cr |
| Reserves | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr |
| Borrowings | ₹4 Cr | ₹5 Cr | ₹6 Cr | ₹3 Cr | ₹5 Cr | ₹2 Cr |
| Other liabilities | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr |
| Total liabilities | ₹15 Cr | ₹18 Cr | ₹18 Cr | ₹15 Cr | ₹16 Cr | ₹18 Cr |
| Fixed assets | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹10 Cr | ₹12 Cr | ₹12 Cr | ₹11 Cr | ₹12 Cr | ₹14 Cr |
| Total assets | ₹15 Cr | ₹18 Cr | ₹18 Cr | ₹15 Cr | ₹16 Cr | ₹18 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
Since Mar 2025, promoters trimmed −15.42 pp while the public added +15.42 pp. The shareholder count shrank 5% to 233.
- Promoters
- 32.9%
- Public
- 67.1%
Since Mar 2025
- Promoters −15.42 pp
- Public +15.42 pp
How it drifted, 12 quarters
Over this window promoters fell from 60.8% to 32.9% — −27.9 pp.
Ownership split by quarter, oldest first. Sep '20: Promoters 60.8%, Public 39.2%.Mar '21: Promoters 60.8%, Public 39.2%.Sep '21: Promoters 60.8%, Public 39.2%.Mar '22: Promoters 60.8%, Public 39.2%.Sep '22: Promoters 60.8%, Public 39.2%.Mar '23: Promoters 60.8%, Public 39.2%.Sep '23: Promoters 60.8%, Public 39.2%.Mar '24: Promoters 60.8%, Public 39.2%.Sep '24: Promoters 57.2%, Public 42.8%.Mar '25: Promoters 48.3%, Public 51.7%.Sep '25: Promoters 31.1%, Public 68.8%.Mar '26: Promoters 32.9%, Public 67.1%.
Who bought this quarter
since Sep 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Anuraag Gambhir newly disclosed 15.05% held
- Harshpaul Singh Takkar newly disclosed 5.79% held
- Suhith Pundalika Bangera newly disclosed 1.90% held
- Mohit Lal Chandani +1.37 pp 6.05% held
- Statsol Research Llp newly disclosed 1.16% held
- Bhoomika Vikram Rao newly disclosed 1.11% held
- Sanath Kulalu newly disclosed 1.02% held
- Reetha Vikram newly disclosed 1.02% held
The same filing shows 6 holders trimming and 11 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of DR LALCHANDANI LABS LIMITED above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Arjan Lal Chandani | 25.69% | +0.05 pp |
| Anuraag Gambhir | 15.05% | newly disclosed |
| Mohit Lal Chandani | 6.05% | +1.37 pp |
| Harshpaul Singh Takkar | 5.79% | newly disclosed |
| Amit Charan | 2.55% | −2.53 pp |
| Laxmipat Dudheria | 2.55% | −0.31 pp |
| Luxmi Kant Gupta | 2.13% | −0.18 pp |
| Suhith Pundalika Bangera | 1.90% | newly disclosed |
| Harsh Kapoor | 1.74% | −1.72 pp |
| Pavana | 1.16% | −1.61 pp |
| Anchal Gupta | 1.16% | +0.33 pp |
| Statsol Research Llp | 1.16% | newly disclosed |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse DR LALCHANDANI LABS LIMITED
Guides on how to read this kind of business and the numbers that matter.